Molecular Pharmacology Program
The Jan Grimm Lab
Research
Professor
The Grimm lab in the Molecular Pharmacology Program focuses on the development of novel and innovative approaches for cancer diagnostics and therapy. These approaches evaluate underlying biology and utilize nanotechnology, chemistry and physics interrogated with modern imaging methods. The lab focuses currently several avenues: (i) the utilization of nanoparticles for cancer therapy; (ii) novel imaging approaches such as Cerenkov and optoacoustic imaging and (iii) the biology of PSMA both in prostate cancer and neovasculature using a tumor-on-chip microfluidic chip system.
Research Projects
Featured News
Publications Highlights
Quo Vadis, Molecular Imaging? Grimm J, Kiessling F, Pichler BJ. J Nucl Med. 2020 Oct;61(10):1428-1434. doi: 10.2967/jnumed.120.241984. Epub 2020 Aug 28. PMID: 32859706.
Synthesis of the PET Tracer 124I-Trametinib for MAPK/ERK Kinase Distribution and Resistance Monitoring.Pratt EC, Isaac E, Stater EP, Yang G, Ouerfelli O, Pillarsetty N, Grimm J. J Nucl Med. 2020 Dec;61(12):1845-1850. doi: 10.2967/jnumed.120.241901. Epub 2020 May 22. PMID: 32444378.
People
Jan Grimm, MD, PhD
Professor
- Radiologist and Nuclear Medicine physician Jan Grimm develops novel approaches for improved diagnosis, monitoring and therapy of prostate and other cancers.
- MD, University of Hamburg (Germany)
- PhD, University of Kiel (Germany)
- [email protected]
- Email Address
- 646-888-3095
- Office Phone
- Download CV
- PDF File
- View physician profile
- Physician profile
Members
- Radiologist
- Dublin City University (Physical Chemistry)
- Material Science and Moelcular Biology
- 646-888-3101
- Lab Phone
- PhD at UPenn
- Training in Urology
- PhD in Chemistry, Georgtown University
- 646-888-3101
- Lab Phone
- PhD in biology, University Hospital Jena, Germany
- University of Koeln, Germany
- PhD in Immunology, State University of Campinas-UNICAMP
- 646-888-3101
- Lab Phone
Lab Alumni
Lab Affiliations
Achievements
- 2014- NIH Nagy New Investigator Award
- 2018- The American Society for Clinical Investigation (ASCI) Member
Open Positions
To learn more about available postdoctoral opportunities, please visit our Career Center
To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs
Get in Touch
-
Lab Head Email
-
Office Phone
-
Office Fax
-
Lab Phone
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Jan Grimm discloses the following relationships and financial interests:
-
Gerson Lehrman Group
Professional Services and Activities -
National Institutes of Health (NIH)
Professional Services and Activities
-
Society of Nuclear Medicine and Molecular Imaging
Professional Services and Activities -
The Hong Kong Polytechnic University
Professional Services and Activities
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].